How to Find the Right AAV CDMO

Searching for an AAV CDMO can look straightforward at first.

There are companies that manufacture adeno-associated virus vectors, and there are sponsors that need those vectors.

The difficulty is that AAV manufacturing is not one uniform process.

Potential partners may differ in production platform, upstream process, downstream purification, analytical capabilities, manufacturing scale, development support, and facility configuration.

So the useful question is not simply:

Which CDMOs manufacture AAV?

It is:

Which AAV CDMO appears capable of supporting this vector, this process, and this stage of development?

That is where the sourcing process becomes more specific.

An AAV CDMO is a contract development and manufacturing organization that supports development or manufacturing of adeno-associated virus vectors.

Depending on the organization, services may include:

• plasmid support
• upstream process development
• vector production
• downstream purification
• analytical development
• formulation
• fill finish
• GMP manufacturing
• stability testing
• clinical supply
• technology transfer

Some AAV CDMOs focus heavily on vector manufacturing.

Others offer broader gene therapy development and manufacturing services.

The right model depends on what the sponsor needs.

One of the first things to understand is how the vector will be produced.

AAV manufacturing can use different production systems and process strategies.

The sponsor should know which platform is being used or developed and whether the CDMO has experience with it.

That may affect:

• facility requirements
• equipment
• scale
• transfection approach
• raw materials
• upstream process
• downstream purification

A manufacturer with strong AAV experience may still be a poor fit if its production platform is not compatible with the sponsor's process.

Upstream manufacturing is where the vector is produced.

Sponsors may need to investigate:

• cell platform
• culture system
• bioreactor configuration
• production scale
• transfection approach
• process-development support
• scale-up strategy

The relevant questions depend on how mature the process already is.

An early-stage company may need significant development work.

A more mature program may primarily need technology transfer and GMP execution.

Purification can be a major part of AAV manufacturing.

The sponsor should understand how the CDMO approaches:

• harvest
• clarification
• concentration
• chromatography
• filtration
• impurity removal
• final formulation

Different purification strategies can affect yield, purity, scalability, and process robustness.

A broad claim that a facility manufactures AAV does not tell you enough about how well its downstream process aligns with your program.

AAV programs may need analytical methods that help characterize full and empty capsids.

This can become important when evaluating vector quality and process performance.

Sponsors should understand which analytical capabilities are available internally and which may be outsourced.

Depending on the program, the broader analytical package may include:

• identity
• potency
• vector genome concentration
• capsid concentration
• purity
• residual impurities
• aggregation
• sterility
• stability

Analytical depth can be one of the meaningful differences between potential AAV manufacturing partners.

AAV manufacturing may depend on plasmid DNA.

The sponsor should understand how plasmids will be sourced and coordinated.

Questions may include:

• Does the CDMO manufacture plasmids internally?
• Are plasmids sourced from an external supplier?
• Who manages the relationship?
• What release requirements apply?
• How does plasmid timing affect AAV manufacturing?

A technically strong vector manufacturing plan can still be delayed if critical upstream materials are not available when needed.

AAV manufacturing scale should be evaluated against the current stage of the program.

Early clinical work may require a different production environment than later-stage manufacturing.

Sponsors should consider:

• development scale
• clinical manufacturing scale
• potential future scale
• batch strategy
• equipment configuration
• expected demand

The largest facility is not automatically the best choice.

The right partner is the one whose manufacturing model fits the program.

An early AAV program may still need substantial work before a robust GMP process exists.

That can include:

• upstream optimization
• transfection optimization
• purification development
• analytical method development
• formulation work
• scale-up

If significant development remains, the quality of the CDMO's development team becomes especially important.

A facility with the right equipment may still be a poor choice if the sponsor needs support the manufacturer is not structured to provide.

A large gene therapy CDMO may operate several facilities.

Those facilities can differ in:

• production platform
• scale
• equipment
• analytical capabilities
• development support
• regulatory history

The sponsor should understand which facility is actually being proposed for the program.

A parent company's overall gene therapy capabilities do not necessarily describe every site it operates.

Facility-level regulatory history should be part of preliminary diligence.

Available FDA Form 483 information can help sponsors identify areas that may deserve closer review.

Sponsors should consider the facility, observations, timing, subsequent regulatory history, and relevance to the proposed AAV manufacturing process.

Formal quality and regulatory qualification remains the sponsor's responsibility.

Specialized AAV manufacturing capacity can be limited.

Once a CDMO appears technically relevant, sponsors should ask about:

• process-development availability
• technology-transfer timing
• plasmid timing
• engineering runs
• GMP manufacturing slots
• analytical lead times
• release testing
• follow-on batches

Current availability should always be confirmed directly with the manufacturer.

Because AAV capabilities can differ between sites within the same company, it is worth asking about the specific facility:

• Which production platform does this site use for AAV?
• Which serotypes or similar programs has the site supported?
• How are full and empty capsids measured and reported?
• Is plasmid DNA produced internally or sourced externally?
• What batch scales are available for the program's next stage?
• When could manufacturing realistically begin?

AAV is one type of viral vector; the broader category is covered in the viral vector CDMO guide. PCN helps AAV sponsors compare facilities on vector-production capabilities, equipment, scale, and regulatory context, then request structured introductions with the manufacturers that appear relevant.